These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1448 related articles for article (PubMed ID: 26620248)

  • 1. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
    Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
    Bailey CJ; Gross JL; Pieters A; Bastien A; List JF
    Lancet; 2010 Jun; 375(9733):2223-33. PubMed ID: 20609968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
    Weber MA; Mansfield TA; Alessi F; Iqbal N; Parikh S; Ptaszynska A
    Blood Press; 2016; 25(2):93-103. PubMed ID: 26623980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
    Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
    Groop PH; Dandona P; Phillip M; Gillard P; Edelman S; Jendle J; Xu J; Scheerer MF; Thoren F; Iqbal N; Repetto E; Mathieu C
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):845-854. PubMed ID: 32946821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
    Heerspink HJ; Johnsson E; Gause-Nilsson I; Cain VA; Sjöström CD
    Diabetes Obes Metab; 2016 Jun; 18(6):590-7. PubMed ID: 26936519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
    Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
    Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
    Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
    Diabetes Obes Metab; 2011 Oct; 13(10):928-38. PubMed ID: 21672123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study.
    Jeong IK; Choi KM; Han KA; Kim KA; Kim IJ; Han SJ; Lee WY; Yoo SJ
    Diabetes Obes Metab; 2024 Nov; 26(11):5065-5077. PubMed ID: 39223856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
    Schumm-Draeger PM; Burgess L; Korányi L; Hruba V; Hamer-Maansson JE; de Bruin TW
    Diabetes Obes Metab; 2015 Jan; 17(1):42-51. PubMed ID: 25200570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.
    Tamborlane WV; Laffel LM; Shehadeh N; Isganaitis E; Van Name M; Ratnayake J; Karlsson C; Norjavaara E
    Lancet Diabetes Endocrinol; 2022 May; 10(5):341-350. PubMed ID: 35378069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
    Rosenstock J; Mathieu C; Chen H; Garcia-Sanchez R; Saraiva GL
    Arch Endocrinol Metab; 2018 Aug; 62(4):424-430. PubMed ID: 30304106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.